Radovich Peter 4

What Happened

• Peter Radovich, President and COO of Mirum Pharmaceuticals (MIRM), had 4,167 restricted stock units (RSUs) convert to common stock on 2026-01-21 (exercise/conversion of derivative). A portion of the resulting shares were sold: 2,382 shares were sold in an open-market transaction on 2026-01-22 at $93.33 per share, generating $222,301. The RSU conversion is recorded at $0.00 (typical for RSUs).

Key Details

• Transaction dates: RSU conversion 2026-01-21; open-market sale 2026-01-22; Form 4 filed 2026-01-23.
• Sale: 2,382 shares at $93.33 = $222,301 total.
• RSU conversion: 4,167 shares converted (recorded at $0.00); some shares were disposed to cover tax withholding.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Relevant footnotes:
  • F1: Each RSU equals a contingent right to one share (or cash at issuer’s discretion).
  • F3: Shares sold to cover tax withholding from RSU vesting.
  • F4: RSUs vest 1/3 each year from Jan 21, 2025 (three-year schedule).
  • F2: Includes 222 shares acquired via the Employee Stock Purchase Plan on Nov 10, 2025.
• Filing timeliness: Form 4 was filed 2026-01-23 for activity on 2026-01-21/22 — appears to be timely (no late filing indicated).

Context

• These were RSU vesting-related actions, not an outright market purchase. The RSU conversion at $0.00 reflects issuance on vesting rather than an option exercise with a cash strike.
• The open-market sale appears to have been used in part to satisfy tax-withholding obligations (routine administrative action), which is common when RSUs vest and does not necessarily indicate a change in insider sentiment.